BACKGROUND: Islet transplantation can restore normoglycemia to patients with unstable type 1 diabetes mellitus, but long-term insulin independence is usually not sustained. Identification of predictor(s) of islet allograft dysfunction (IGD) might allow for early intervention(s) to preserve functional islet mass. METHODS: Fourteen islet transplantation recipients with long-term history of type 1 diabetes mellitus underwent metabolic testing by mixed meal tolerance test, intravenous glucose tolerance test, and arginine stimulation test every 3 months postislet transplant completion. Metabolic responses were compared between subjects who maintained insulin independence at 18 months (group 1; n=5) and those who restarted insulin within 18 months (group 2; n=9). Data were analyzed before development of islet graft dysfunction and while insulin independent. RESULTS: The 90-min glucose, time-to-peak C-peptide, and area under the curve for glucose were consistently higher in group 2 and increased as a function of time. At 12 months, acute insulin release to glucose in group 2 was markedly reduced as compared with baseline (5.62+/-1.21 microIU/mL, n=4 vs. 16.14+/-3.69 microIU/mL, n=8), whereas it remained stable in group 1 (22.36+/-4.98 microIU/mL, n=5 vs. 27.70+/-2.83 microIU/mL, n=5). Acute insulin release to glucose, acute C-peptide release to glucose (ACpRg), and mixed meal stimulation index were significantly decreased and time-to-peak C-peptide, 90-min glucose, and area under the curve for glucose were significantly increased when measured at time points preceding intervals where IGD occurred compared with intervals where there was no IGD. CONCLUSIONS: The intravenous glucose tolerance test and mixed meal tolerance test may be useful in the prediction of IGD and should be essential components of the metabolic testing of islet transplant recipients.
BACKGROUND: Islet transplantation can restore normoglycemia to patients with unstable type 1 diabetes mellitus, but long-term insulin independence is usually not sustained. Identification of predictor(s) of islet allograft dysfunction (IGD) might allow for early intervention(s) to preserve functional islet mass. METHODS: Fourteen islet transplantation recipients with long-term history of type 1 diabetes mellitus underwent metabolic testing by mixed meal tolerance test, intravenous glucose tolerance test, and arginine stimulation test every 3 months postislet transplant completion. Metabolic responses were compared between subjects who maintained insulin independence at 18 months (group 1; n=5) and those who restarted insulin within 18 months (group 2; n=9). Data were analyzed before development of islet graft dysfunction and while insulin independent. RESULTS: The 90-min glucose, time-to-peak C-peptide, and area under the curve for glucose were consistently higher in group 2 and increased as a function of time. At 12 months, acute insulin release to glucose in group 2 was markedly reduced as compared with baseline (5.62+/-1.21 microIU/mL, n=4 vs. 16.14+/-3.69 microIU/mL, n=8), whereas it remained stable in group 1 (22.36+/-4.98 microIU/mL, n=5 vs. 27.70+/-2.83 microIU/mL, n=5). Acute insulin release to glucose, acute C-peptide release to glucose (ACpRg), and mixed meal stimulation index were significantly decreased and time-to-peak C-peptide, 90-min glucose, and area under the curve for glucose were significantly increased when measured at time points preceding intervals where IGD occurred compared with intervals where there was no IGD. CONCLUSIONS: The intravenous glucose tolerance test and mixed meal tolerance test may be useful in the prediction of IGD and should be essential components of the metabolic testing of islet transplant recipients.
Authors: Niraj M Desai; John A Goss; Shaoping Deng; Bryan A Wolf; Eileen Markmann; Maral Palanjian; Angela P Shock; Sue Feliciano; F Charles Brunicardi; Clyde F Barker; Ali Naji; James F Markmann Journal: Transplantation Date: 2003-12-15 Impact factor: 4.939
Authors: R N Faradji; K Monroy; S Messinger; A Pileggi; T Froud; D A Baidal; P E Cure; C Ricordi; L Luzi; R Alejandro Journal: Am J Transplant Date: 2006-12-06 Impact factor: 8.086
Authors: J D Brunzell; R P Robertson; R L Lerner; W R Hazzard; J W Ensinck; E L Bierman; D Porte Journal: J Clin Endocrinol Metab Date: 1976-02 Impact factor: 5.958
Authors: E A Ryan; J R Lakey; R V Rajotte; G S Korbutt; T Kin; S Imes; A Rabinovitch; J F Elliott; D Bigam; N M Kneteman; G L Warnock; I Larsen; A M Shapiro Journal: Diabetes Date: 2001-04 Impact factor: 9.461
Authors: Edmond A Ryan; Jonathan R T Lakey; Breay W Paty; Sharleen Imes; Gregory S Korbutt; Norman M Kneteman; David Bigam; Ray V Rajotte; A M James Shapiro Journal: Diabetes Date: 2002-07 Impact factor: 9.461
Authors: D Hirsch; J Odorico; J S Danobeitia; R Alejandro; M R Rickels; M Hanson; N Radke; D Baidal; D Hullett; A Naji; C Ricordi; D Kaufman; L Fernandez Journal: Am J Transplant Date: 2012-02-02 Impact factor: 8.086
Authors: Heba M Ismail; Carmella Evans-Molina; Linda A DiMeglio; Dorothy J Becker; Ingrid Libman; Emily K Sims; David Boulware; Kevan C Herold; Lisa Rafkin; Jay Skyler; Mario A Cleves; Jerry Palmer; Jay M Sosenko Journal: Pediatr Diabetes Date: 2019-04-15 Impact factor: 4.866
Authors: A Shishido; A Caicedo; R Rodriguez-Diaz; A Pileggi; P-O Berggren; M H Abdulreda Journal: CellR4 Repair Replace Regen Reprogram Date: 2016-07-26
Authors: K A Benedict; S Moassesfar; S Adi; S E Gitelman; J L Brennan; M McEnhill; P G Stock; A A Portale; A M Posselt Journal: Am J Transplant Date: 2013-06-13 Impact factor: 8.086
Authors: S Forbes; R A Oram; A Smith; A Lam; T Olateju; S Imes; A J Malcolm; A M J Shapiro; P A Senior Journal: Am J Transplant Date: 2016-04-21 Impact factor: 8.086